Topics. When to treat? Smoldering vs Symptomatic Choice of Induction regimen Role of HDT Role of consolidation/maintenance
|
|
- Melanie Wilson
- 5 years ago
- Views:
Transcription
1 Initial Therapy Sagar Lonial, MD Chair and Professor Department of Hematology and Medical Oncology Chief Medical Officer, Winship Cancer Institute Emory University School of Medicine
2 Topics When to treat? Smoldering vs Symptomatic Choice of Induction regimen Role of HDT Role of consolidation/maintenance
3 Criteria for Diagnosis of Myeloma MGUS < 3 g M spike < 10% plasma cells SMM 3 g M spike 10% plasma cells Active MM 10% plasma cells M spike + AND AND No anemia, bone lesions, normal calcium, and kidney function Anemia, bone lesions, high calcium, or abnormal kidney function MGUS = monoclonal gammopathy of unknown significance; SMM = smoldering multiple myeloma. Kyle et al, 2009.
4 Not all Smoldering patients are the same 27% will convert in 15 years Roughly 2% per year Kyle R et al. N Engl J Med 2007;356:
5 Free Light is Useful for Risk Assessment in AMM Dispenzeri et al Blood 2008
6 Updated IMWG Criteria for Diagnosis of Multiple Myeloma MGUS M-protein < 3 g/dl Clonal plasma cells in BM < 10% No myeloma defining events Smoldering Myeloma M-protein 3 g/dl (serum) or 500 mg/24 hrs (urine) Clonal plasma cells in BM 10% - 60% No myeloma defining events Multiple Myeloma Underlying plasma cell proliferative disorder AND 1 or more myeloma defining events including either: 1 CRAB feature(s) OR 1 Biomarker Driven C: Calcium elevation (> 11 mg/dl or > 1 mg/dl higher than ULN) R: Renal insufficiency (creatinine clearance < 40 ml/min or serum creatinine > 2 mg/dl) A: Anemia (Hb < 10 g/dl or 2 g/dl < normal) B: Bone disease ( 1 lytic lesions on skeletal radiography, CT, or PET-CT) Biomarker driven (1) Sixty-percent ( 60%) clonal PCs by BM; (2) serum free Light chain ratio involved:uninvolved 100; (3) >1 focal lesion detected by MRI Rajkumar SV, et al. Lancet Oncol. 2014;15:e538-e548.
7 ECOG/SWOG: Phase III Asymptomatic Myeloma*(PI: SL) Lenalidomide vs. observation No Dex to isolate the effect of len R A N D O M IZ A TI O N Lenalidomide Observation CR/PR/ Stable Prog. anytime Continue therapy till prog. or toxicity Off Rx Control/standard arm
8 Ongoing Investigations RD + Dara RD+ Pembro/nivo Vaccine + len + Durva KRD auto transplant KRD KRD + Dara auto KRD Len
9 PETHEMA Cure with old Drugs Functional cure? Martinez-Lopez et al, Blood 2011
10 Survival outcomes in newly diagnosed myeloma patients with RVD induction among all patients (at a median follow up of 66 months) Nooka et al, unpublished
11 Three Drugs Are Better Than Two ORR VGPR TD RD VD VTD VCD RVD
12 Induction regimens in MM Progression Free Survival Overall Survival Nooka et al. Cancer DOI: /cncr.28325
13 Impact of IMIDs on OS and PFS with translocations Barwick et al
14 CR and VGPR rates in high risk subgroups of patients Does it matter which 3 drugs are used? P<0.001 P<0.001 P=0.155 P<0.001 Cavo et al, Leukemia 2016 Responses to both VTD and VCD were reassessed centrally
15 Randomized Trial VTD vs VCD Shows superiority of IMID/PI VCD is no longer a reasonable induction choice Moreau et al, Blood 2016
16 RVD is better than VCD Compass trial, IA9
17 SWOG S0777 Study Design (continued) VRd Rd After induction Rd Maintenance Until PD, Toxicity or Withdrawal Lenalidomide 25 mg PO days 1-21 Dexamethasone 40 mg PO days 1, 8,15, 22 All patients received Aspirin 325 mg/day VRd patients received HSV prophylaxis Durie et al, Lancet
18 Confirmed Response*: VRd versus Rd VRd Rd CR 15.7% 8.4% VGPR 27.8% 23.4% PR 38% 39.7% ORR (PR or better) 81.5% 71.5% SD 15.7% 24.3% SD or better 97.2% 95.8% PD or Death 2.8% 4.2% *Assessable patients Durie et al, Lancet
19 Progression-Free Survival By Assigned Treatment Arm Log-rank P value = (one sided)* HR = (0.560, 0.906)* *Stratified *Assessable patients Durie et al, ASH Durie et al, Lancet
20 Overall Survival By Assigned Treatment Arm HR = (0.516, 0.973)* Log-rank P value = (two sided)* *Stratified *Assessable patients 20 Durie et al, Lancet
21 Where are we? Risk stratify Smoldering IMID/PI combination is the standard of care Which PI?
22 KRD for newly diagnosed Myeloma
23 Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, KRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone du Myélome (IFM) KRd Phase II Study NCT M. Roussel, V. Lauwers-Cances, N. Robillard, K. Belhadj, T. Facon, L. Garderet, M. Escoffre, B. Pegourie, L. Benboubker, D. Caillot, C. Fohrer, P. Moreau, X. Leleu, H. Avet-Loiseau, and M. Attal for the IFM
24 STUDY DESIGN Induction KRd day cycles Carfilzomib/Len/Dex PBSC harvest: Cyclophosphamide high dose Intensification HD Melphalan 200 mg/m2 Open-label, multicenter, phase II study in frontline MM pts < 65 yrs KRd Induction Carfilzomib 20-36mg/m2 D1, 2, 8, 9, 15, 16 Lenalidomide 25 mg D1-21 Dexamethasone 20 mg1-2, 8-9, 15-16, Mandatory LMWH KRd Consolidation Consolidation KRd day cycles Carfilzomib/Len/Dex Carfilzomib 36mg/m2 D1,2, 8, 9, 15, 16 Lenalidomide 25 mg D1-21 Dexamethasone 20 mg D1, D8, D15, D22 Maintenance Lenalidomide 10mg D cycles (1 year) MRD evaluation for VGPR pts (CMF/NGS)
25 RESPONSE RATES at the completion of Consolidation N=46 n % scr MRD - CMF MRD - NGS 23/34 68 At least CR At least VGPR ORR PD patients were not evaluable due to toxicities MRD CMF 10-4 /10-5 MRD NGS clonoseq Adaptive 10-6
26 RESPONSE RATES Post Induction Post ASCT Post Consolidation Best Response n n n n % scr CR+sCR VGPR VGPR or better PR ORR PD 1 1 1
27 CARDIO-VASCULAR + PULMONARY TOXICITIES all grades 25 CARDIAC AND VASCULAR EVENTS Total No of events No of patients (%) Cardiac Failure 2 2 (4) Pulmonary Embolism 2 2 (4) Venous Thrombosis 2 2 (4) Intra Cardiac Thrombus 1 1 (2) Superfical Thrombosis 8 8 (17) Bradycardia 2 2 (4) Arrhythmia 1 1 (2) Atrial Fibrillation 1 1 (2) Tachycardia 1 1 (2) Hypertension 5 4 (9) Cough 11 9 (20) Dyspnea 5 5 (11)
28 IRD Response Rates Kumar SK, et al. Lancet Oncol. 2014;15(13):
29 Ixazomib-Lenalidomide-Dexamethasone (IRd) combination before and after ASCT followed by Ixazomib maintenance in patients with newly diagnosed multiple myeloma: a phase 2 study from the Intergroupe Francophone du Myélome (IFM) P Moreau, C Hulin, D Caillot, G Marit, A Perrot, L Garderet, T Facon, L Benboubker, L Karlin, M Tiab, B Arnulf, JP Fermand, X Leleu, C Touzeau, M Roussel, L Planche, H Caillon, S Minvielle, MC Béné, H Avet-Loiseau, T Dejoie, M Attal
30 Study design 1- Induction: 3 cycles of Ixazomib RD, every 28 days - Ixazomib 4 mg/d; D1, 8, 15 - Lenalidomide 25 mg/d ; D1 to 21 - Dexamethasone 40 mg/d; D1, 8, 15, PBSC harvest Mobilization: Cyclophosphamide 3 g/m 2 and G-CSF 5 µg/kg 3- Peripheral stem cell transplantation Melphalan 200 mg/m 2 4- Early consolidation : 2 cycles of Ixazomib/Len/Dex, every 28 days 5- Late consolidation: 6 cycles of Ixazomib/Len (without Dex), every 28 days 6 Maintenance therapy for 1 year (13 cycles) Ixazomib weekly 4 mg D1, 8, 15, every 28 days
31 Responses intent-to-treat Post-induction N = 42 Post-ASCT N = 42 Post-early Conso N = 42 Post-late Conso N = 42 scr (%) CR (%) VGPR (%) PR (%) Stable (%) PD (%) NE (%) > PR (%) > VGPR (%) > CR (%)
32 Intent-to-treat / feasibility During induction : 2 PD, 1 Rash Feasibility ASCT: 37 / 42 (88%) ASCT: no toxic death, no PD Feasibility: 37 / 42 Early consolidation : no SAE, 1 PD Feasibility: 37 / 42 Late consolidation: 1 SAE (rash), 1 PD Feasibility 34 / 42 (81%) Maintenance ongoing : 1 thrombocytopenia precluding maintenance, 2 PD
33 Safety (excluding ASCT, and maintenance) AEs leading to exclusion - During induction : 1 rash - Late consolidation: 1 rash - Before maintenance: 1 thrombocytopenia 12 cases of non-hematologic grade 3-4 toxicities were reported: -infections (8 cases), -abdominal pain (2), -atrial fibrillation (1), -thrombosis (1) No cardiac failure, no ischemic heart disease, no renal impairment No grade 3-4 peripheral neuropathy
34 ELO+ RVD phase II study Screening Induction therapy and Transplant Maintenance 28-day cycles Follow Up Newly Diagnosed Multiple Myeloma 4 cycles Elo-RVD Stem Cell Mobilization ASCT NO ASCT YES 4 cycles Elo-RVD Autologous Stem Cell Transplantation High Risk: Elotuzumab Lenalidomide Bortezomib Dexamethasone Low Risk: Elotuzumab Lenalidomide Dexamethasone Follow Up Visits every 3 months Laubach et al, ASH 2016
35 Response After 4 Cycles Laubach et al, ASH 2016
36 On-study death and treatment discontinuations due to AEs One patient died on study Hospitalized due to respiratory failure and sepsis during cycle 2 and subsequently died as a result of these AEs One patient died > 30 days after discontinuing study therapy Patient became acutely ill during cycle 1, hospitalized for febrile neutropenia and hypotension related to sepsis, then developed renal failure. Participant was removed from study and died more than 30 days later. Five additional patients discontinued from treatment due to the following AEs: Grade 3 peripheral neuropathy, discontinues treatment after cycle 3 Grade 3 mood disturbance, discontinues treatment after cycle 3 Grade 4 hyperglycemia, discontinues treatment after cycle 2 Grade 3 orthostatic hypotension and demyelinating polyneuropathy, d/c s treatment after cycle 4 Grade 3 lung infection, discontinues treatment after cycle 2 Laubach et al, ASH 2016
37 Where are we? Risk stratify Smoldering IMID/PI combination is the standard of care Which PI? Bz has the most data, randomized trials in progress Role of HDT?
38 Registration RVD 1 Lenalidomide + Bortezomib + Dexamethasone 25mg/d (d1 to 14) 1.3mg/m 2 (d 1, 4, 8, 11) 20mg/d (d1,2,4,5,8,9,11,12) Randomization (stratified on ISS and FISH) ) IFM 2009 : Study Design. Arm A Arm B RVD 2 and 3 RVD 2 and 3 PBSC Collection (cyclophosphamide 3g/m 2 and G-CSF) 10mcg/kg/d) RVD 4 to 8 PBSC Collection (cyclophosphamide 3g/m 2 and G-CSF) ASCT HDM 200mg/m2 RVD 4 and 5 Lenalidomide Maintenance 12 months (10-15 mg/d) Lenalidomide Maintenance 12 months (10-15 mg/d)
39 IFM 2009: Best Response. RVD arm N=350 Transplant arm N=350 p-value CR 49% 59% VGPR 29% 29% 0.02 PR 20% 11% <PR 2% 1% At least VGPR 78% 88% Neg MRD by FCM, n (%) 228 (65%) 280 (80%) 0.001
40 IFM 2009: PFS (9/2015) HDT no HDT Patients (%) P< N at risk HDT no HDT Months of follow-up
41 IFM 2009: OS (9/2015) Patients (%) P NS 10 0 HDT no HD T N at risk HDT no HDT Months of follow-up
42 KRD outcomes by Transplant Status Jakubowiak et al, EHA 2016
43 Getting to Minimal Residual Disease (MRD): New Definitions for CR Newly diagnosed S.S. Patient Disease burden CR Stringent CR MRD Molecular/Flow CR Antibodies Maintenance Therapy?Cure? 0.0
44 Outcomes for patients are the same if they achieved MRD negativity MRD at post-maintenance 1.0 Patients without progression (%) /3 of these patients were from HDT, 1/3 from delayed HDT P-value (trend) : p< <10-6 [10-6;10-5[ [10-5;10-4[ >= N at risk (events) <10-6 [10-6 ;10-5 [ [10-5 ;10-4 [ [10-4 ;10-3 [ (0) 86 (0) 86 (0) 86 (0) 86 (5) 77 (3) 61 (5) 36 (0) (0) 29 (0) 29 (0) 29 (0) 28 (5) 22 (3) 16 (4) 4 (1) 1 23 (0) 23 (0) 23 (0) 23 (1) 22 (3) 19 (2) 14 (5) 3 (0) 2 40 (0) 40 (0) 40 (0) 40 (6) 33 (9) 23 (6) 15 (4) 4 (1) 2 30 Months since randomization
45 Where are we? Risk stratify Smoldering IMID/PI combination is the standard of care Which PI Bz has the most data, randomized trials in progress Role of HDT Continues to offer benefit in achievement of MRD- Role of consolidation/maintenance
46 Up-front single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial) Michele Cavo*, Maria Teresa Petrucci, Francesco Di Raimondo, Elena Zamagni, Barbara Gamberi, Claudia Crippa, Giulia Marzocchi, Mariella Grasso, Stelvio Ballanti, Donatella Iolanda Vincelli, Paola Tacchetti, Massimo Offidani, Giampietro Semenzato, Anna Marina Liberati, Anna Pascarella, Giulia Benevolo, Rossella Troia, Angelo D. Palmas, Nicola Cantore, Rita Rizzi, Fortunato Morabito, Mario Boccadoro, and Pieter Sonneveld On behalf of EMN02/HO95 MM Trial participants * Seragnoli Institute of Hematology, Bologna University School of Medicine, Italy
47 PFS by randomization 1 (HDM-1 vs HDM-2) 1.00 % Probability 0.50 HDM-2 HDM-1 PFS median, mos NR NR PFS at 3 yrs, % Number at risk HDM2 HDM1 HR (95% CI): 0.70 ( ); p = months HDM2 HDM1 Median follow-up: 32 months (IQR 26-41)
48 PFS by high-risk cytogenetics 1.00 % Probability Number at risk HDM2 HDM1 HDM-2 HDM-1 PFS median, mos PFS at 3 yrs, % HR (95% CI): 0.49 ( ); p = months HDM2 HDM1
49 EMN02 / HOVON 95 MM A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma (NTR2528, Eudract ) The European Intergroup Trial of the European Myeloma Network EMN
50 Sonneveld et al. ASH 2016 Design of EMN02 trial 4 VCD + Stem cell apheresis R1 4 VMP HDM 1/2 R2 2 VRD None Registration Induction Stem cell mobilization in all pts Early or late ASCT, once or twice Consolidation MRD Lenalidomide Lenalidomide Maintenance until relapse HDM/ASCT at 1 st relapse [Accessed March 2015]
51 100 Progression-free free survival Cumulative percentage no consolidation VRD N 435 F 137 no consolidation VRD Cox LR P=0.045 (adjusted for 1st random.) At risk: no consolidation VRD HR = 0.78 ( ) months Sonneveld et al. ASH 2016 EMN02 / HO95 MM 51
52 Stadtmauer et al. ASH 2016
53 Stadtmauer et al. ASH 2016
54 Stadtmauer et al. ASH 2016
55 Where are we? Risk stratify Smoldering IMID/PI combination is the standard of care Which PI Bz has the most data, randomized trials in progress Role of HDT Continues to offer benefit in achievement of MRD- Role of consolidation Limited role, tandem transplant does not offer benefit Role of Maintenance
56 Overall Survival: Median Follow-Up of 80 Months There is a 26% reduction in risk of death, representing an estimated 2.5- year increase in median survival a yr OS Survival Probability Patients at risk N = 1209 LENALIDOMIDE CONTROL Median OS (95% CI), mos HR (95% CI) P value NE (NE-NE) 0.74 ( ) ( ) Overall Survival, mos 50% 62% a Median for lenalidomide treatment arm was extrapolated to be 116 months based on median of the control arm and HR (median, 86 months; HR = 0.74). HR, hazard ratio; NE, not estimable; OS, overall survival.
57 Overall Survival: Subgroup Analysis Age Sex ISS stage Response after ASCT Prior induction therapy < 60 yrs 60 yrs M a le F e m a le I o r II III CR CR/VGPR PR/SD/PD LEN Non-LEN Yes No LEN a CONTROL a HR (95% CI) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) < 5 0 m L /m in ( ) Adverse-risk cytogenetics b 5 0 m L /m in ( ) ( ) CrCl after ASCT c HR Favors LEN Favors control ( )
58 Suggested Approach for Newly Diagnosed MM Transplant Eligible Yes No RVD Std RIsk High RIsk Failure to achieve VGPR Car/Pom/Dex Maintenance High RIsk Early Transplant Del 17p Other high risk features RVD Maintenance t(4:14) Std RIsk Bz Maintenance Early vs Delayed Transplant Len Maintenance Rd, Vd, RVD-lite MPV Del 17p Other high risk features RVD Maintenance t(4:14) Bz Maintenance Nooka et al, JOP 2016
59 Emory OS by Genetics N= 256 all patients received RVD High risk all received 3 drug maintenance Minimal exposure to alkylators Nooka et al, Leukemia 2013
60 New directions IMID/PI is the standard of Care for Newly diagnosed MM, question on optimal PI remains the subject of trials Transplant continues to have an important role in quest to achieve MRD negativity Tandem in US patients not standard Maintenance is not one size fits all 4 drug induction is on the way
61 Thanks to: Jonathan Kaufman Charise Gleason Danni Cassabourne Melanie Watson Donald Harvey Renee Smith Colleen Lewis Amelia Langston L.T. Heffner Ebeneezer David Claire Torre S-Y Sun Jing Chen Fadlo Khuri Leon Bernal Larry Boise IMS Golfers Against Cancer T.J. Martell Foundation And Many Others who are part of the B-cell Team
Induction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationIn-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) in transplant eligible
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationMyeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco
Myeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco Survival in Myeloma IFM DFCI; 2015 2011-14 2001-10 1961-70 1991-2000 Kumar S.
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More informationCME Information: Multiple Myeloma: 2016 update on Diagnosis, Risk-stratification and Management
CME ARTICLE AJH CME Information: Multiple Myeloma: 2016 update on Diagnosis, Risk-stratification and Management CME Editor: Ayalew Tefferi, M.D. Author: S. Vincent Rajkumar, M.D. If you wish to receive
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationMSN, ANP-BC, AOCNP1*, R.
R2V2: Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study Jonathan L. Kaufman, MD
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationMultiple Myeloma Transplant and Non-transplant Modalities
Multiple Myeloma Transplant and Non-transplant Modalities Sikander Ailawadhi, MD Associate Professor of Medicine Division of Hematology-Oncology Mayo Clinic, Jacksonville, Florida 15 th Annual Miami Cancer
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationMultiple Myeloma in the Elderly: When to Treat, When to Go to Transplant
Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationShould some patients with Smoldering Myeloma receive treatment? Yes-High Risk SMM should S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Should some patients with Smoldering Myeloma receive treatment? Yes-High Risk SMM should S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
More informationMultiple myeloma. November 24, 2017 at Vientiane, Laos
Multiple myeloma November 24, 2017 at Vientiane, Laos Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi, Mahidol University, Thailand Multiple myeloma
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationSerum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial
Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationLong-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma (MM): Phase 2 study
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationMultiple Myeloma: Diagnosis, Prognosis, and Treatment. Jeffrey A. Zonder, MD Professor of Oncology Karmanos Cancer Institute
Multiple Myeloma: Diagnosis, Prognosis, and Treatment Jeffrey A. Zonder, MD Professor of Oncology Karmanos Cancer Institute General Themes Smoldering Myeloma: Diverging Philosophies Newly Diagnosed Myeloma:
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationReview of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM
Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More information